Silver Nanoparticles Penetrate Mucus Barriers for Respiratory Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cystic fibrosis patients face challenges with frequent and chronic respiratory infections due to thick mucus that traps bacteria, making it difficult for conventional antibiotics to penetrate and effectively treat drug-resistant bacterial infections such as Burkholderia cepacia and Pseudomonas aeruginosa.
Innovation Solution
Nonionic, ground state, spherical nanoparticles are administered via inhalation, capable of penetrating thick mucus layers to reach underlying respiratory tissue and bacteria within biofilms, while being non-toxic and easily cleared from the body, effectively killing or deactivating targeted microbes without releasing significant silver or metal ions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are administered via inhalation, then they can reach the respiratory tissue, but they cannot effectively penetrate the thick mucus and biofilm layers to reach the bacteria
Solution Approach 1:
The patent changes the physical parameters of the antibiotic delivery system by using nanoparticles with specific size ranges (1-100 nm diameter) and surface properties. These nanoscale parameters enable penetration through mucus and biofilm barriers that conventional-sized antibiotics cannot penetrate, while maintaining therapeutic effectiveness against the bacteria.
Solution Approach 2:
The patent uses inhalation as an intermediary delivery method that transports nanoparticles through the respiratory tract. The inhalation process serves as a mediator that delivers the nanoparticle-antibiotic complex directly to the infected respiratory tissue, bypassing the limitations of systemic administration and overcoming the mucus barrier more effectively.
2Reliability
If systemic administration of antibiotics is used, then infected epithelia can be reached, but reinfection readily occurs because bacteria remain in the thick overlying mucus
Solution Approach 1:
The patent segments the treatment approach by dividing the delivery system into nanoscale particles that can independently penetrate through different layers (mucus, biofilm, and tissue). This segmentation allows simultaneous reach to both the bacteria in the mucus and the infected epithelia underneath, eliminating the persistent reservoir problem.
Solution Approach 2:
The patent changes the size parameter of the antibiotic carrier to nanoscale dimensions (1-100 nm), which enables the antibiotics to traverse the thick mucus layer and reach bacteria that were previously inaccessible. This parameter change allows effective treatment of both the mucus-associated bacteria and the underlying infected tissue.
3Reliability
If larger nanoparticle sizes are used, then they may have better stability, but they cannot effectively penetrate the mucus layers
Solution Approach 1:
The patent optimizes the nanoparticle size parameter to a specific range (1-100 nm diameter) that balances two competing requirements: small enough to penetrate mucus and biofilm layers effectively, yet large enough to maintain structural stability and carry sufficient antibiotic load. This parameter optimization resolves the contradiction between size-dependent penetration and size-dependent stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles effectively treat respiratory infections by penetrating mucus and biofilms, reducing the risk of side effects and reinfection, and are versatile in treating various antibiotic-resistant bacteria and fungal pathogens, with low toxicity and efficient clearance from the body.
Implementation Method 1
The treatment compositions described herein are able to effectively penetrate thick, viscous mucus layers to reach targeted microbes within the mucus and to reach underlying respiratory tissue
Implementation Method 2
a plurality of nonionic, ground state, spherical nanoparticles with no external edges or bond angles mixed in or mixable within a carrier formulated for administration to a patient via inhalation
Implementation Method 3
nanoparticles having a mean diameter of about 8 nm, have been found to effectively penetrate mucus while still being capable of effective clearance from the patient's body (e.g., via the lymphatic system and kidneys)
Data Source
AI summary
This disclosure relates to silver nanoparticle compositions and methods for treating respiratory infections, such as one or more of a bacterial, fungal, or viral infection. A treatment composition comprising nonionic, ground state silver nanoparticles and a carrier is administered to a patient's lungs via inhalation. The silver nanoparticles have properties that enable effective transport through biofilm and mucus layers to epithelia and surrounding tissues, killing or deactivating microbes at the targeted respiratory tissue and throughout the overlying mucus layer without the release of silver ions and without damaging respiratory tissue.